Nivolumab plus ONC201 plus in microsatellite stable (MSS) metastatic colorectal cancer (mCRC) patients: a Brown University Oncology Research Group phase Ib/II study (BrUOG379).

Khaldoun AlmhannaRimini BreakstoneAlexander RaufiRoxanne WoodAmy WebberSopha DionsonLindsay CavanaghAttila A SeyhanHoward SafranWafik El-Deiry

Published in: Translational gastroenterology and hepatology (2024)

In this study of patients with advanced MSS CRC, combination ONC201/nivolumab was well-tolerated; objective responses to ONC201/nivolumab were not observed.

Keyphrases

end stage renal disease
metastatic colorectal cancer
chronic kidney disease
newly diagnosed
palliative care
prognostic factors
peritoneal dialysis
patient reported
genetic diversity